FDA grants priority review to Eagle’s NDA for Ryanodex
In January 2014, the company filed its NDA with the FDA for the treatment of malignant hyperthermia, a condition that can be triggered when genetically susceptible individuals come
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
A manufacturing agreement that covers all aspects of the production of the encapsulated live cells has been signed by Nuvilex and Austrianova. An initial payment has been made
MCT-485 is a very small noncoding double stranded RNA (dsRNA) molecule which has demonstrated a unique cytotoxic, oncolytic, and immune stimulating activity in in vitro models of hepatocellular